Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Development of a subunit vaccine for prevention of Clostridium difficile associated diseases: Biophysical characterization of toxoids A and B.

Gribenko A, Severina E, Sidhu MK, Jansen KU, Green BA, Matsuka YV.

Biochem Biophys Rep. 2017 Jan 5;9:193-202. doi: 10.1016/j.bbrep.2016.12.015. eCollection 2017 Mar.

2.

High Resolution Mapping of Bactericidal Monoclonal Antibody Binding Epitopes on Staphylococcus aureus Antigen MntC.

Gribenko AV, Parris K, Mosyak L, Li S, Handke L, Hawkins JC, Severina E, Matsuka YV, Anderson AS.

PLoS Pathog. 2016 Sep 30;12(9):e1005908. doi: 10.1371/journal.ppat.1005908. eCollection 2016 Sep.

3.

Demonstration of the preclinical correlate of protection for Staphylococcus aureus clumping factor A in a murine model of infection.

Scully IL, Timofeyeva Y, Keeney D, Matsuka YV, Severina E, McNeil LK, Nanra J, Hu G, Liberator PA, Jansen KU, Anderson AS.

Vaccine. 2015 Oct 5;33(41):5452-5457. doi: 10.1016/j.vaccine.2015.08.029. Epub 2015 Aug 28.

4.

Three-dimensional structure and biophysical characterization of Staphylococcus aureus cell surface antigen-manganese transporter MntC.

Gribenko A, Mosyak L, Ghosh S, Parris K, Svenson K, Moran J, Chu L, Li S, Liu T, Woods VL Jr, Jansen KU, Green BA, Anderson AS, Matsuka YV.

J Mol Biol. 2013 Sep 23;425(18):3429-45. doi: 10.1016/j.jmb.2013.06.033. Epub 2013 Jul 1.

PMID:
23827136
5.

A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile.

Donald RGK, Flint M, Kalyan N, Johnson E, Witko SE, Kotash C, Zhao P, Megati S, Yurgelonis I, Lee PK, Matsuka YV, Severina E, Deatly A, Sidhu M, Jansen KU, Minton NP, Anderson AS.

Microbiology. 2013 Jul;159(Pt 7):1254-1266. doi: 10.1099/mic.0.066712-0. Epub 2013 Apr 29.

6.

A recombinant clumping factor A-containing vaccine induces functional antibodies to Staphylococcus aureus that are not observed after natural exposure.

Hawkins J, Kodali S, Matsuka YV, McNeil LK, Mininni T, Scully IL, Vernachio JH, Severina E, Girgenti D, Jansen KU, Anderson AS, Donald RG.

Clin Vaccine Immunol. 2012 Oct;19(10):1641-50. Epub 2012 Aug 15.

7.

Structural and biochemical characterization of Staphylococcus aureus clumping factor B/ligand interactions.

Ganesh VK, Barbu EM, Deivanayagam CC, Le B, Anderson AS, Matsuka YV, Lin SL, Foster TJ, Narayana SV, Höök M.

J Biol Chem. 2011 Jul 22;286(29):25963-72. doi: 10.1074/jbc.M110.217414. Epub 2011 May 3.

8.

Heterogeneous in vivo expression of clumping factor A and capsular polysaccharide by Staphylococcus aureus: implications for vaccine design.

Nanra JS, Timofeyeva Y, Buitrago SM, Sellman BR, Dilts DA, Fink P, Nunez L, Hagen M, Matsuka YV, Mininni T, Zhu D, Pavliak V, Green BA, Jansen KU, Anderson AS.

Vaccine. 2009 May 26;27(25-26):3276-80. doi: 10.1016/j.vaccine.2009.01.062. Epub 2009 Feb 5.

PMID:
19200819
9.

Expression of Staphylococcus epidermidis SdrG increases following exposure to an in vivo environment.

Sellman BR, Timofeyeva Y, Nanra J, Scott A, Fulginiti JP, Matsuka YV, Baker SM.

Infect Immun. 2008 Jul;76(7):2950-7. doi: 10.1128/IAI.00055-08. Epub 2008 Apr 21.

10.

Proteomic analysis and identification of Streptococcus pyogenes surface-associated proteins.

Severin A, Nickbarg E, Wooters J, Quazi SA, Matsuka YV, Murphy E, Moutsatsos IK, Zagursky RJ, Olmsted SB.

J Bacteriol. 2007 Mar;189(5):1514-22. Epub 2006 Dec 1.

11.
12.

Structure of the streptococcal cell wall C5a peptidase.

Brown CK, Gu ZY, Matsuka YV, Purushothaman SS, Winter LA, Cleary PP, Olmsted SB, Ohlendorf DH, Earhart CA.

Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18391-6. Epub 2005 Dec 12.

13.

The pro-sequence domain of streptopain directs the folding of the mature enzyme.

Anderson ET, Winter LA, Fernsten P, Olmsted SB, Matsuka YV.

Arch Biochem Biophys. 2005 Apr 15;436(2):297-306.

PMID:
15797242
14.
15.

Identification of factor XIIIA-reactive glutamine acceptor and lysine donor sites within fibronectin-binding protein (FnbA) from Staphylococcus aureus.

Anderson ET, Fletcher L, Severin A, Murphy E, Baker SM, Matsuka YV.

Biochemistry. 2004 Sep 21;43(37):11842-52.

PMID:
15362870
16.
17.

Processing, stability, and kinetic parameters of C5a peptidase from Streptococcus pyogenes.

Anderson ET, Wetherell MG, Winter LA, Olmsted SB, Cleary PP, Matsuka YV.

Eur J Biochem. 2002 Oct;269(19):4839-51.

18.

Toxoids of streptococcal pyrogenic exotoxin A are protective in rabbit models of streptococcal toxic shock syndrome.

Roggiani M, Stoehr JA, Olmsted SB, Matsuka YV, Pillai S, Ohlendorf DH, Schlievert PM.

Infect Immun. 2000 Sep;68(9):5011-7.

19.

Development of streptococcal pyrogenic exotoxin C vaccine toxoids that are protective in the rabbit model of toxic shock syndrome.

McCormick JK, Tripp TJ, Olmsted SB, Matsuka YV, Gahr PJ, Ohlendorf DH, Schlievert PM.

J Immunol. 2000 Aug 15;165(4):2306-12.

20.
21.

Characterization of a subunit structure and stability of the recombinant porin from Neisseria gonorrhoeae.

Matsuka YV, Dilts DA, Hoiseth S, Arumugham R.

J Protein Chem. 1998 Oct;17(7):719-28.

PMID:
9853688
22.

Cross-linking of fibronectin to C-terminal fragments of the fibrinogen alpha-chain by factor XIIIa.

Matsuka YV, Migliorini MM, Ingham KC.

J Protein Chem. 1997 Nov;16(8):739-45.

PMID:
9365922
23.

Factor XIIIa-catalyzed cross-linking of recombinant alpha C fragments of human fibrinogen.

Matsuka YV, Medved LV, Migliorini MM, Ingham KC.

Biochemistry. 1996 May 7;35(18):5810-6.

PMID:
8639541
26.

Supplemental Content

Loading ...
Support Center